Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isaxonine SCHEMBL1270289 | 0.85 | KCNH3 (0.43) | MAPK1ALDH1A1KMT2AMEN1HTT | |
| Isaxonine SCHEMBL9030532 | 0.85 | PKM (0.40) | MAPK1ALDH1A1KMT2AMEN1NPC1 | |
| Isaxonine SCHEMBL4537710 | 0.82 | FDPS (0.42) | MAPK1KMT2AMEN1NPC1RAB9A | |
| Carbamic Acid SCHEMBL2847023 | 0.79 | ABL1 (0.48) | MAPK1ALDH1A1HCAR3KDM4E | |
| SCHEMBL1225937 | 0.78 | MEN1 (0.42) | MAPK1ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL1225938 | 0.78 | MEN1 (0.42) | MAPK1ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL8683599 | 0.74 | MAPK1 (0.52) | MAPK1ALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL26319653 | 0.74 | FFAR2 (0.41) | MAPK1ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL19243702 | 0.74 | ALDH1A1 (0.45) | MAPK1ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL13127917 | 0.73 | HTT (0.46) | MAPK1ALDH1A1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7820687-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231185-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | Elan Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100016345-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-7579466-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1996559-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007101165-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016345-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, CD4 | MAPK1 2459/4885ALDH1A1 443/4885KMT2A 975/4885 |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | MAPK1 3793/4885ALDH1A1 1095/4885KMT2A 2607/4885 |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, CD4 | MAPK1 2459/4885ALDH1A1 443/4885KMT2A 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.